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Abstract 
Background and Aims: Cancer cells with high metastatic potential and stem cell 
like characteristics express the cell surface marker CD44. However, the molecular 
mechanism of action of CD44 in tumor progression and metastasis remains elusive. 
We sought to explore the impact of CD44v6 signaling in pancreatic cancer growth 
and metastasis. 
Methods: Tumor cells expressing different CD44 isoforms including CD44v6 and v6 
peptides interfering with the CD44v6 co-receptor function for Met and VEGFR-2 were 
tested in syngeneic rat (ASv6), orthotopic murine (FC1245-KPC) and human (L3.6pl, 
Panc1) as well as patient derived tumor xenografts (PDTX, JoPaca-1). The CD44v6 
peptide was further tested in the KPC (LSL-KrasG12D/+, LSL-Trp53R172H/+, Pdx1-Cre) 
genetically engineered mouse (GEM) model. The expression of CD44v6 transcripts 
was interrogated in RNA-sequencing data from 136 pancreatic cancer patients. 
Results: CD44v6 was found to be a prerequisite for pancreatic cancer metastasis. 
The pro-metastatic effect of CD44v6 was reversed by Met knockdown. Inhibitory 
CD44v6 peptides reduced the metastatic tumor burden in all models. Intriguingly, 
regression of already established metastatic lesions was observed after CD44v6 
blockade. Elevated tumor CD44v6 expression was associated with enhanced Met 
expression and correlated with poor patient survival and increased metastasis. 
CD44v6 inhibition correlated with reduced Met-dependent cell migration/invasion, 
enhanced ligand-induced apoptosis and reduced VEGFR-2-dependent angiogenesis. 
Of note, CD44v6 inhibition more efficiently prevented metastasis compared to 
mono/dual Met (Crizotinib) and VEGFR-2 (Pazopanib) inhibition.  
Conclusion: Therefore, CD44v6 organizes a signaling hub for pancreatic cancer 
metastasis hence providing an attractive novel therapeutic target for this devastating 
disease.  
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Introduction 
Metastatic tumor growth remains the major reason for cancer treatment failure.1 Early 
distant dissemination is a characteristic feature of the most aggressive types of 
cancers, among which is pancreatic cancer, leading to poor prognosis. Metastatic 
cells have acquired specific properties distinguishing them from the locally growing 
tumor cells. These features are determined by key proteins controlling cell behavior 
and cell fate. One such protein is CD44, a family of transmembrane glycoproteins 
involved in many cellular processes including proliferation, migration, and survival 
(reviewed by Orian-Rousseau2). Family members differ in the extracellular domain 
where 10 variant exons are either excluded or included in various combinations. 
There is ample evidence for increased expression of CD44 isoforms in tumor 
progression and metastasis (reviewed by Zoller3). In addition, CD44 is present on 
several types of cancer stem cells. Previous approaches aimed at targeting these 
cellular subpopulations, for example, via delivery of toxins with limited preclinical and 
clinical success (reviewed by Orian-Rousseau and Ponta4). 
CD44v6, a CD44 family member, is critical for signaling as a co-receptor for receptor 
tyrosine kinases (RTKs) such as MET, recepteur d'origine nantais (Ron), and 
vascular endothelial growth factor receptor-2 (VEGFR-2) (reviewed by Orian-
Rousseau2). MET is involved in biological processes such as migration, invasion, 
proliferation, survival, and epithelial remodeling, crucial steps for dissemination of 
tumor cells.5 Overexpression, mutations, or mis-expression of MET or its ligand 
hepatocyte growth factor (HGF)/scatter factor has been observed in a wide range of 
cancers.6 The cooperation between CD44v6 and MET involves both the ectodomain 
of CD44v6 as well as the cytoplasmic domain. In several cancer cell lines as well as 
in primary cells, HGF-induced MET phosphorylation depends on CD44v6.7 Scanning 
mutations in the exon v6 located in the CD44v6 ectodomain showed the importance 
of 3 amino acids in the center of this exon.8 These amino acids are RWH in human, 
GWQ in mouse, and EWQ in rat. Peptides covering these 3 amino acids block MET 
activation in many different cell systems.8 and 9 CD44v6 also collaborates with 
VEGFR-2, which plays a critical role in angiogenesis.10 The CD44v6 peptides also 
can block VEGF-induced VEGFR-2 activation and signaling.9 
Together, these data add to the relevance of CD44v6 signaling in tumor growth and 
metastasis. Therefore, we aimed to investigate the impact of CD44v6 in pancreatic 
cancer metastasis. Here, we show that this co-receptor function of CD44v6 for MET 
is the driving force for metastasis in several independent pancreatic cancer models. 
Furthermore, small peptides interfering with CD44v68 block metastatic spreading 
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and, most importantly, lead to regression of already established metastases. These 
effects of the CD44v6 peptide, especially on distant metastases, suggest a potential 
for treatment of pancreatic cancer, a fast metastasizing cancer. 
 
 
Results  
Both CD44v6 and MET Control Metastatic Spreading of Rat Pancreatic Tumor 
Cells 
Only CD44 isoforms containing exon v6 sequences with any combination with other 
variant exons, including CD44v6,7, CD44v4-7, or CD44v1-10, can act as co-
receptors for the RTK MET.7 In the rat pancreatic carcinoma BSp73AS cells 
expressing only CD44s, MET cannot be activated by HGF unless a CD44v6-
containing isoform is expressed (Figure 1A), in line with previous observations. 7 
Moreover, exon v6 removal in CD44v1-10Δv6 impaired MET activation (Figure 1A). 
To test whether the CD44v6 co-receptor function for MET would be necessary for 
induction of the metastatic potential in nonmetastatic BSp73AS cells, BSp73AS cells 
expressing different CD44 isoforms were injected subcutaneously into syngeneic 
rats. In all cases, a primary tumor was detected ( Supplementary Table 1). Strikingly, 
only in the case of ASv6 (designated CD44v6) and ASv1-10 (designated CD44v1-
v10) cells were metastases detected in the axillary lymph nodes at the injection site 
(Figure 1B and  Supplementary Table 1). No pulmonary metastases were detected in 
animals injected with parental cells or cells transfected with CD44v1-10Δv6 
(Figure 1B and Supplementary Table 1), whereas CD44v6 and CD44v1-v10–
transfected cells efficiently colonized the lungs. We then tested whether MET 
inactivation also prevented metastasis. Importantly, the metastatic potential 
conferred by the CD44v6 isoforms was MET-dependent, as shown by knock-down 
experiments. ASv6 cells infected with lentivirus-expressing MET shRNA sequences14 
(Figure 1A, last 2 lanes) were injected (or cells expressing control shRNA 
sequences) subcutaneously into rats. All animals developed primary tumors even 
upon knock-down of MET. However metastasis was abrogated ( Figure 1B and 
Supplementary Table 1). MET activation was observed only in primary tumors 
expressing control shRNA, but not MET shRNA (Figure 1C). 
Our experiments showed that CD44v6 and MET are required together for metastatic 
spreading of CD44v6-transfected AS cells. 
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CD44v6 Peptides Inhibit Metastasis of Rat Pancreatic Tumor Cells 
We identified 3 species-specific amino acids encoded by exon v6 that are relevant 
for the CD44v6 co-receptor function.8 Peptides of 5-14 amino acids length containing 
the 3 crucial amino acids inhibit HGF-induced MET and downstream Erk activation 
as efficiently as a CD44v6 blocking antibody (Figure 2A), in line with our previous 
observations. 8 In addition, the PI3K/Akt pathway was impaired as detected by 
phospho-AKT Western blot (Figure 2A). We examined whether this interfering 
peptide also would inhibit CD44v6-dependent metastasis. ASv6 cells were injected 
subcutaneously into syngeneic rats and 1 week later the rat CD44v6 peptide 
(designated rv6pep), a control peptide, or the CD44v6 blocking antibody was injected 
intratumorally ( Supplementary Figure 2) or intravenously (Figure 2B–D) 3 times a 
week for 3 weeks. Treatment with the v6 blocking antibody or with rv6pep had no 
effect on primary tumor growth ( Figure 2B and Supplementary Table 2). Importantly, 
metastasis was completely inhibited by rv6pep and the CD44v6 monoclonal antibody 
(Figure 2C and D, Supplementary Table 2, and shown for BSp73AS cells expressing 
CD44v4-715). 
The specificity of the CD44v6 peptides binding to the tumor and to the metastases 
in vivo was shown using DY681-labeled peptide in near-infrared fluorescence 
imaging with the Optix MX2 (ART, Montreal, Canada) (Supplementary Figure 3). 
Taken together, our experiments strongly suggest that the CD44v6 co-receptor 
function for MET is a crucial step for metastatic spreading in the rat syngeneic 
pancreatic tumor model and that CD44v6 peptides not only inhibit metastasis 
formation but also specifically target local and metastatic tumor cells in vivo. 
 
In an Orthotopic Syngeneic Murine Pancreatic Model a CD44v6 Peptide 
Decreases Tumorigenesis and Prevents Metastasis 
The KPC (LSL-KrasG12D/+, LSL-Trp53R172H/+, Pdx1-Cre) mice carrying a pancreatic-
specific Trp53R172H mutation alongside an initiating mutation in KrasG12D recapitulate 
the pathophysiological and molecular features of human pancreatic ductal 
adenocarcinoma (PDAC).16 These mice develop invasive metastatic PDAC with an 
extensive stroma and, in common with human PDAC, are insensitive to therapy. 
13 and 17 
FC1245 cells are pancreatic carcinoma cells derived from these KPC mice. In these 
cells MET activation could be inhibited by treatment with mv6pep and with the 
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MET kinase inhibitor crizotinib, approved for lung cancer,18 but not with rv6pep 
(control peptide) (Figure 3A). Furthermore, the HGF-dependent migration of these 
cells, as monitored by a scratch assay, was blocked in a concentration-dependent 
fashion by mv6pep and crizotinib (Supplementary Figure 4). Orthotopic 
transplantation of FC1245 cells into syngeneic mice gave rise to pancreatic 
carcinoma with metastases in liver, spleen, and kidney (Supplementary Table 3). 
Upon treatment of the animals with crizotinib, both tumor growth and metastasis 
were inhibited (Figure 3B and C). Most importantly, mv6pep treatment also reduced 
primary tumor growth and metastasis. This effect was even stronger than that 
observed with crizotinib ( Figure 3B and C and Supplementary Table 3). MET 
activation in the tumors using phospho-MET staining as readout was completely 
inhibited by mv6pep treatment, but only partially inhibited by crizotinib (Figure 3D). 
Direct treatment of KPC mice with mv6pep after they already had developed clinically 
detectable palpable pancreatic tumors and metastases19 resulted in a dramatic 
prolongation of their life span (Figure 3E). 
 
Growth of Primary Tumor and Metastasis of Human Pancreatic Cancer Cells Is 
Inhibited by a Human CD44v6 Peptide 
To expand our studies to human pancreatic tumors we made use of the highly 
metastatic human pancreatic carcinoma cells L3.6pl11 and the highly tumorigenic 
primary human pancreatic tumor cells JoPaca-1, characterized by a high expression 
of cancer stem cell markers and a high clonogenic potential in vitro and in vivo.20 In 
both systems MET activation is CD44v6-dependent (Figure 4A) (as reviewed by 
Tremmel et al 9). We orthotopically injected these cells into immune-compromised 
mice. These mice developed primary tumors after 1 week, and numerous 
metastases after 3–4 weeks with L3.6pl and 10 weeks with JoPaca-1 cells 
(Supplementary Tables 4 and 5). The primary tumors expressed large amounts of 
CD44v6 (Figure 4C). Of note, the body weight of animals in the JoPaca-1 Patient 
Derived Tumor Xenograft (PDTX) model did not significantly change after peptide 
treatment for a long time period (eg, 80 days) ( Figure 4B). 
MET was activated in the tumor sections as shown in the case of the L3.6pl cells 
(Supplementary Figure 6A). Intraperitoneal injection of hv6pep 3 times per week for 3 
weeks completely repressed MET activation (Supplementary Figure 6A), showing 
interference of the peptide with the CD44v6 co-receptor function for MET. Because 
MET activation is species-specific and the human MET receptor can be activated 
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only by human HGF, 21 this result suggests that L3.6pl cells produce their own HGF. 
Indeed, human HGF at a concentration of 1470 pg/mL was detected in the L3.6pl 
supernatants after 5 days of culture (Supplementary Figure 6B). Interestingly, the v6 
peptide repressed this HGF secretion ( Supplementary Figure 6B). 
The outgrowth of the orthotopic human (L3.6pl and JoPaca-1) (Figure 4C) and 
murine (FC1245) ( Figure 3B) tumors was strongly repressed by hv6pep and 
mv6pep, respectively. This is in contrast to the subcutaneously growing rat model ( 
Figure 2B). One explanation is that the local growth of the rat model is primarily 
independent of CD44v6 and MET ( Figure 2B and Supplementary Table 1). Hence, 
the tumor originally was selected to survive the artificial subcutaneous 
microenvironment, and introduction of CD44v6 expression confers only a 
prometastatic effect that could be abrogated by the v6 peptide. Furthermore, 
treatment with hv6pep decreased angiogenesis in the L3.6pl orthotopic model 
(Supplementary Figure 6C) similar to our observation with mv6pep. 9 Because the v6 
peptides are species-specific, angiogenesis inhibition by hv6pep cannot be the result 
of an effect on the murine endothelial cells in the xenograft systems but rather of an 
inhibition of VEGF production by the human cells. Indeed, L3.6pl cells produce 
hVEGF, a secretion that can be blocked with the hv6pep (Supplementary Figure 6B). 
Of note, VEGFR-2 activation in vivo was reduced by hv6pep treatment 
(Supplementary Figure 6A). 
The most striking observation with the human pancreatic tumor models was the 
strong inhibition of metastasis by hv6pep (Figure 4D and Supplementary Tables 4 
and 5) as compared with the rat-specific control peptide. 
Finally, our findings were recapitulated with another model, namely the orthotopic 
injection of Panc1 cells22 in immune-compromised mice (Supplementary Figure 7 
and Supplementary Table 6). 
Because the CD44v6 peptide inhibits primary tumor growth and metastasis of human 
pancreatic cancer cells in the tested tumor models, the CD44 co-receptor function for 
MET and VEGFR-2 might be involved in human pancreatic cancer. We examined 
CD44v6, MET, and VEGFR-2 expression using RNA-seq data of human pancreatic 
cancer patients (Figure 4E and Supplementary material). The patient cohort was 
divided into 2 clusters according to tumor CD44v6 high (up) vs CD44v6 low (down) 
expression. In the CD44v6 up group patients had a significantly increased odds ratio 
of metastasis of 44%, vs 23% of patients in the v6 down group (P = .01). 
Furthermore, patients in the v6 up group had a significant (∼4-fold) increase in 
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median expression of MET ( Figure 4E) (P = .01, adjusted Bonferroni). There was no 
significant difference in the mean expression of VEGFR-2. Patients with high tumor 
expression of v6-containing transcripts had a significantly shorter median survival of 
approximately 13 months compared with patients with low tumor v6 expression 
(median survival, 18 mo; P = .02; log-rank) ( Figure 4F). 
Because the CD44v6 peptide also interferes with MET8 and VEGFR-2 function,9 we 
then tested whether inhibition of both RTKs with a combination of inhibitors would 
have a similar effect as the peptide alone. To this aim, we compared the efficacy of 
hv6pep on primary tumor growth and metastasis with treatment with crizotinib or 
pazopanib. Of note, both inhibitors already are approved for the treatment of human 
cancers.18 and 23 Crizotinib has been described previously. Pazopanib targets several 
RTKs, including VEGFR-2. Both inhibitors repressed primary tumor outgrowth, 
particularly when used together, similar to the treatment with hv6pep (Figure 5A). In 
addition, liver metastasis was hampered by both inhibitors, again most effective 
when used in combination ( Figure 5B and C). However, this repression was much 
less effective than treatment with hv6pep ( Figure 5B and C). 
 
Already Established Metastases Are Eliminated by CD44v6 Peptides 
To decisively explore whether the CD44v6 peptides can be used in a therapeutic 
setting on already established metastases, we injected ASv6 cells subcutaneously 
into syngeneic rats and L3.6pl cells orthotopically into nude mice and let them grow 
for 3 weeks, when all animals from the control groups had developed metastases 
(Supplementary Table 6). The animals then were treated either with the species-
specific CD44v6 peptides or with control peptides 3 times per week for another 3 
weeks (Figure 6A and B), and then were screened for metastases. As expected, 
metastases could be detected in all animals treated with the control peptides ( 
Supplementary Table 6 and Figure 6A and B), whereas nearly all animals treated 
with the species-specific CD44v6 peptides were metastasis-free. Thus, already 
established metastases can be eliminated by treatment with the CD44v6 peptides. 
We next examined the lung for apoptosis using cleaved caspase-3 or caspase-8 as a 
read-out. Apoptotic cells were detected as early as 3 days after the first peptide 
injection in tumor areas of animals treated with rv6pep, but not with the control 
peptide ( Figure 7). Maximum apoptosis was measured 8 days after the first peptide 
injection. At day 22, no metastases could be detected anymore in rv6pep-treated 
animals (Figure 7). 
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We then tested the efficiency of the peptide treatment in prolonging the survival of 
the animals. One week after injection of L3.6pl cells (when the animals already 
developed tumors as detected in the control group) (Figure 6C), animals were 
treated with hv6pep for 35 days. At that time (42 days), the tumors of the treated 
animals were reduced drastically but all control animals were moribund. Treatment 
then was stopped and the animals were observed for an additional 45 days. None of 
the remaining animals was moribund, but the primary tumor size did increase slightly, 
indicating tumor recurrence (Figure 6C). At autopsy, no macrometastases were 
observed in these animals. 
 
Discussion  
Here we show the critical relevance of CD44v6-dependent signaling in metastatic 
outgrowth of pancreatic tumor cells in human, rat and murine models. From the 
therapy perspective, we report intriguing inhibition of tumor growth and metastasis 
via blockade of CD44v6 signaling in a large series of orthotopic pancreatic cancer 
i.e., in well-characterized therapy refractory KPC-GEM and JoPaca-1 PDTX models. 
This effect was in part via activation of at least two key metastasis-associated 
pathways, Met and VEGFR-2, respectively. Consequently, CD44v6 neutralizing 
peptides blocked Met and VEGFR-2 activation and abrogated the metastatic 
spreading of pancreatic tumor cells. Moreover, inhibition of CD44v6 signaling 
showed superior efficacy in orthotopic models over single or combined Met and 
VEGFR-2 RTK inhibitors currently used in the clinic. Hence CD44v6 signaling might 
control additional metastatic circuitries beyond its co-receptor function for Met and 
VEGFR-2. Indeed, the regression of already established tumors and their 
metastases upon induction of apoptosis by treatment with the CD44v6 peptides 
could be due to inhibition of Met/VEGFR-2 or another CD44v6-mediated survival 
signal that re-sensitizes tumor cells to apoptosis. Together, these data suggest a 
central role for CD44v6 signaling in metastatic spreading and maintenance of 
metastases in distant organs.  
CD44v6 expression is restricted to proliferative tissues, but is up-regulated in a 
variety of cancers (reviewed in1). This makes CD44v6 a prime target for cancer 
therapy. Humanized monoclonal blocking antibodies have been developed and were 
used in clinical trials (reviewed in2). However, previous approaches aimed at 
targeting the CD44v6 expressing cells via toxins or radionuclides. This was due to 
the lack of knowledge of its modulatory role as an integral signaling hub. 
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Nonetheless, despites promising activities at an early clinical stage, the CD44 
targeting trials were stopped due to the death of one patient during a phase I dose 
escalation study with a CD44v6 antibody coupled to the cytotoxic drug mertansine 
(reviewed in2). Of note, radio-labeled antibodies demonstrated a favorable toxicity 
profile. From the current perspective, and the here presented data, targeting CD44v6 
signaling rather than ablative approaches via delivery of toxins to CD44v6 expressing 
tumors may constitute a more promising and least toxic strategy.  
The fact that the CD44v6 peptide not only interferes with the metastatic spreading of 
tumor cells but even leads to regression of already established metastases makes it 
a very promising tool for cancer therapy, particularly for treatment of pancreatic 
cancer, the fifth leading cause of cancer death. In fact, the five years survival rate in 
the range of 3-5% is the lowest amongst all cancers, the main reason being the 
aggressive metastatic potential of this cancer type. Gemcitabine monotherapy and 
more recently approved chemotherapy combinations FOLFIRINOX and 
nabPaclitaxel-gemcitabine only modestly improve survival in advanced pancreatic 
cancer.  
The critical role of HGF/Met in carcinogenesis prompted the development of tools 
such as Met or HGF inhibitors to interfere with the malignant processes3-5. 
Unfortunately all these tools were not as successful in the clinics as suggested by the 
animal experiments.  This lack of success might be due to the fact that targeting only 
one protein is not sufficient. To substantially impact the treatment of pancreatic 
cancer patients development of novel rationally designed multimodal therapy 
strategies are urgently needed. An advantage of the CD44v6 peptide for therapy is 
that it targets not only Met activation but also that of other RTKs relevant for 
tumorigenesis, such as VEGFR-2 and thereby interferes as well with angiogenesis6. 
In this regard it is interesting that the metastatic spreading of pancreatic islet in the 
RIP-Tag2 mice is decreased when the animals were treated not only with VEGFR 
inhibitors but in addition also with Met inhibitors7. Simultaneous inhibition of tumor 
cell centric phenomenon such as cell viability and invasiveness as well as blockade 
of tumor angiogenesis by CD44v6 neutralizing peptide may therefore provide a 
powerful dual strategy to combat the intricate processes involved in formation and 
growth of metastatic lesions.  
Synthetic inhibitors have been developed that target simultaneously Met and 
VEGFR-2. One of these compounds, Cabozantinib is already FDA-approved8. 
Cabozantinib, demonstrated encouraging randomized Phase II data9. However, 
despite improved progression-free-survival no significant overall-survival benefit was 
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found after Cabozantinib treatment of castration-resistant metastatic prostate cancer 
patients as compared to prednisone control arm in the COMET-1 phase III trial  
(http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=1962549). A 
drawback of these inhibitors is that they very often induce drug resistance and side 
effects. CD44v6 and Met-expressing tumor cells are protected against drug-induced 
apoptosis10. Thus, the CD44v6 peptide might protect against drug resistance in 
combination regimen.  
CD44 has been identified as a bona fide stem cell marker on many cancer types 
including pancreatic carcinoma11. Only in few cases, however, the specific CD44 
isoform that correlates with stemcellness has been identified. One such case is 
breast cancer where a CD44v6+/CD24low population of cells has stem-cell 
characteristics12. CD44v6 has also been described as a stem cell marker for 
colorectal cancer13 where it is involved in the maintenance of stemcellness and 
pancreatic tumors14. High Met-expression was also detected on populations of 
cancer stem cells, e.g. in head and neck squamous cell carcinoma15. Particularly 
interesting is the finding that Met and CD44 are stem cell markers on pancreatic 
carcinoma16 suggesting that the co-receptor function of CD44 for Met might be of 
functional importance in these cells. Of note, an antibody against CD44, claimed 
however to recognize CD44s only, was shown to inhibit pancreatic tumor initiation17.  
The fact that already established metastases can be eliminated by treatment with 
CD44v6-specific peptides demonstrates that CD44v6 is required for the growth and 
maintenance of metastases at least in part via its co-receptor function. In line with 
our observation, the requirement of CD44v6 and Met for the metastatic spreading of 
colorectal cancer was recently reported18. Additionally, CD44v6 and Met could be 
also required for the preparation of the metastatic niche. CD44v6 expressing 
pancreatic carcinoma cells seem to prepare a pre-metastatic niche by sequestration 
of exosomes19 and establishment of an extracellular matrix that allows growth and 
survival. Furthermore Met drives a genetic program that provides a fibrin matrix 
supporting cell proliferation and invasion20.  
In conclusion, we provide evidence for rationale design of CD44v6 targeting therapy 
to prevent- or eradicate pancreatic cancer metastasis. CD44v6 plays a critical role as 
co-receptor of key metastasis regulating signaling such as Met, VEGFR and 
potentially other, not hitherto discovered pathways. Therefore, this strategy may 
demonstrate some advantages over current single modality approaches. The 
superior efficacy compared to selective RTK inhibition suggests that CD44v6 
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targeting therapy may control multiple pathophysiological processes governing tumor 
invasion and metastasis. 
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Materials and Methods 
Cell Lines 
Rat pancreatic carcinoma cells BSp73AS (designated “AS”) and transfectants have 
been described.7 Human pancreatic cancer cells L3.6pl were kindly provided by C. 
Bruns11 (University of Magdeburg, Germany). FC1245 cells were thankfully obtained 
from D. Tuveson (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), and were 
cultured in RPMI 1640 (ATCC, Wesel, Germany) and 10% fetal calf serum (FCS). 
Panc1 cells (ATCC) were maintained in Dulbecco’s modified Eagle medium and 10% 
FCS. Primary JoPaca-1 cells were kindly provided by Dr Hoheisel (Deutsches 
Krebsforschungszentrum, Heidelberg, Germany) and cultured in Iscove's modified 
Dulbecco's Medium (Life Technologies, Darmstadt, Germany) and 10% FCS. 
Antibodies and Other Reagents 
The monoclonal antibody VFF18 that specifically recognizes human CD44v6 was 
from Bender (Vienna, Austria), the anti-extracellular signal-regulated kinase (ERK)1 
(K-23), Met (C-28), and Green Fluorescent Protein (GFP) antibodies (sc-101525) 
were from Santa Cruz Biotechnology (Heidelberg, Germany), the cleaved caspase-8 
antibody (IMG-5703) was from Imgenex (San Diego, CA), the CD31 antibody 
(MEC13.3) was from BD Biosciences (Heidelberg, Germany), and the cleaved 
caspase-3 (Asp175), Phospho-Met (Tyr1234/1235) (D26), Met (25H2), and the 
phospho-ERK phospho-p44/42 antibodies were from Cell Signaling Technology 
(Beverly, England). The rat exon v6-specific antibody 1.1ASML has been 
described.12 Secondary antibodies labeled with horseradish peroxidase were from 
Dako (Glostrup, Denmark). The Alexa Fluor R 546 goat anti-rabbit secondary 
antibody was from Life Technologies. HGF was from Peprotech (Hamburg, 
Germany). The rv6pep (KEKWFENEWQGKNP), mv6pep (QETWFQNGWQGKNP), 
and hv6pep (KEQWFGNRWHEGYR) have been described.8 and 9 Solubility of hv6 
pep is 15 mg/mL in phosphate-buffered saline, and 16 mg/mL for rv6pep. Half-life in 
serum for hv6pep is 11 minutes, and 55 minutes for the first degradation product, a 
12mer containing the critical amino acids that suffice for inhibition (Supplementary 
Figure 1). Here, we used the 14mer peptides, but all experiments also were repeated 
with 5mer peptides and provided similar results. For in vivo imaging experiments the 
rat 11mer WFENEWQGKNP, the mouse (WFQNGWQGKNP), and human 
(WFGNRWHEGYR) 11mer were labeled with the fluorescent dye DY681. The 
hv6pep was used as a control peptide in the rat model, and rv6pep was used in the 
human and mouse orthotopic tumor models. Peptides were from Bachem 
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(Bubendorf, Switzerland) or Intavis (Köln, Germany). Lyophylized peptides were 
resuspended in phosphate-buffered saline. 
Animal Experiments 
Male athymic nude mice (NCI-nu) were purchased from Harlan (Roßdorf, Germany). 
BDX rats were bred in house. Animals were housed and maintained under specific 
pathogen-free conditions in facilities approved by the Regierungspräsidium 
Karlsruhe. All animals were handled according to German regulations for animal 
experimentation. Experiments were authorized by the Regierungspräsidium (35-
9185.817G-192/10 and 35-9185.817G-106/09). LSL-KrasG12D, LSL-Trp53R172H, and 
Pdx1-Cre (KPC) mice have been described previously. 13 
Patient Samples 
All studies were approved by the Ethics Committee of the University of Heidelberg in 
Germany, and written informed consent was obtained from all patients. Biopsy 
specimens were immediately collected, snap-frozen in liquid nitrogen, and stored at -
80°C. 
Additional information on animal experiments and protocols for immunoblotting, 
lentiviral transfection of short hairpin RNA (shRNA), cell migration assay, quantitative 
determination of HGF and VEGF, serum stability, in vivo fluorescence imaging, 
histology, immunofluorescence, and transcriptome analysis of patient samples can 
be found in the Supplementary Materials and Methods section. 
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Figure legends 
Figure 1. The CD44v6 co-receptor function for Met is required for tumor 
metastasis.  
A Top: CD44 constructs for transfection of AS cells. Bottom: AS cells and 
transfectants were induced with HGF where indicated and Met/ERK activation was 
determined. Numbers refer to the fold induction as calculated by the computer 
program ImageJ. Experiments were performed at least three times and gave similar 
results.   
B Left: Cells used in A were subcutaneously injected into the posterior flank of 
syngeneic rats. Pictures represent axillary lymph nodes and lungs isolated four 
weeks after implantation. Arrows indicate metastases. The number of animals used 
is given in Table 1. Right: Scheme representing the metastatic behavior of 
transfectants. Quantification of the average number of metastases. 
C Immunohistochemical analysis of ASv6 tumors infected with lentivirus expressing 
ctrl shRNA or Met shRNA. Sections were stained with an anti-GFP antibody to 
monitor shRNA-transduced areas or with a phospho-Met antibody. A representative 
picture is shown. Ten animals per group (Table 1) were analyzed. Magnification 20x. 
 
Figure 2. A CD44v6 specific peptide blocks metastasis of rat tumor cells.  
A ASv6 cells were induced with HGF in the presence of rv6pep, a CD44v6 specific 
antibody (1.1ASML) or a control peptide (mouse) as indicated. Met, ERK and Akt 
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activation was determined using phospho-specific antibodies. Numbers refer to the 
fold induction.  
B ASv6 cells were injected subcutaneously into the right posterior flank of BDX rats. 
Average tumor volume in rats treated as indicated was determined at the end of the 
experiments. The group size is given in Table 1 and 2.  
C Pictures represent axillary lymph nodes and lungs. Treatment with the rv6pep 
(i.v.), the control peptide or the CD44v6 antibody started one week after implantation. 
Arrows indicate metastases. The group size is given in Table S2. 
D Top: Chart showing the average number of metastases. Bottom: Representative 
lung sections of animals treated with rv6pep or with the control peptide stained with 
H&E and PAS are shown.  Magnifications 1,5x, 4,5x and 20x.  
 
 
Figure 3. A CD44v6 peptide prevents metastasis of mouse tumor cells in a 
pancreatic cancer orthotopic model.  
A FC1245 cells were induced with murine HGF after incubation with mv6pep, a 
control peptide (rat; both 0,025µM) or Crizotinib (0,5µM) as indicated. Met and ERK 
activation was determined using phospho-specific antibodies. Numbers refer to fold 
induction. 
B FC1245 cells were injected orthotopically into the pancreas of male C57BL/6 mice 
as described21. One week later animals were injected i.p. with mv6pep or control 
peptide (20 µg). Injection was repeated three times per week. Crizotinib was applied 
daily orally at 25 mg/kg. Animals were killed 14 days after beginning of the treatment. 
Average tumor volume at autopsy is represented.  
C Top: Organs of the animals in B at autopsy were examined for macroscopic 
metastases. A representative picture is shown. Bottom: Graph representing the liver 
metastases number.  
D Top: H&E staining of tumors isolated from animals treated either with mv6pep, 
control peptide or Crizotinib (left). Representative immunofluorescence stainings of 
primary tumors for phospho-Met (middle) and Met (right). Nuclei are stained with 
DAPI. Bottom: Quantification of phospho-Met in the primary tumor.   
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E  Kaplan-Meier survival analysis of tumor-bearing KPC mice treated three times per 
week with either mv6pep (red line, n = 5) or control peptide (blue line, n = 5). P 
values, Log Rank. 
 
 
 
Figure 4.  A CD44v6 peptide interferes with metastasis of human tumor cells in 
a pancreatic cancer orthotopic model.  
A L3.6pl (left) or JoPaca-1 (right) cells were treated with hv6pep or the control 
peptide (rat) prior to induction with HGF. Met, ERK and Akt activation was 
determined in western blot. The experiment was repeated at least five times. 
B Body weight determination of animals injected with JoPaca-1 cells and treated with 
hv6pep or control pep. 
C L3.6pl or JoPaca-1 cells were injected orthotopically into the pancreas of male 
nude mice. One week later animals were injected i.p. with hv6pep or control peptide 
(20 µg). Injection was repeated three times per week. Animals were killed at the 
indicated days.  The quantification represents the average tumor volume of animals 
treated either with hv6pep or the control peptide at the end of the experiment. 
Tumors were stained for CD44v6 (VFF18). A representative picture is shown. Nuclei 
were stained with hematoxylin (L3.6pl). Analysis of five animals per group gave 
similar results. 
 
D Top: Macroscopic liver and kidney metastases from hv6pep or control peptide 
treated animals of the experiment in C. Bottom: Bars show the average number of 
metastases.   
E Top: Expression of CD44 transcripts in pancreatic cancer patients. Patient samples 
were clustered into two groups according the expression levels of v6 containing 
transcripts (v6 high Up, red) vs. v6 low (Down, blue) groups. Bottom:	   Boxplot 
showing the relative increase in expression of Met in v6 Up group compared to the 
v6 Down group. Relative Met expression (log2) to the median of the v6 down cohort 
are presented. The patient group with high CD44v6 expression has a ~ four-fold 
increase in median expression of MET (p=0.01, adjusted Bonferroni).  
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F  A significant decrease in median overall survival (~13 months) for patients with 
high expression levels of v6 transcripts (red line) compared to patients with low 
expression of v6 transcripts (18 months, blue line) was found (p=0.02). 
 
Figure 5. The CD44v6 peptide reduces metastasis more efficiently than small 
molecule inhibitors.  
A The average tumor volume of mice (n=5) with orthotopic L3.6pl tumors is 
represented after three weeks treatment with the indicated compounds. 
B Average number of metastases is represented in a graph. White arrows on 
pictures indicate metastases.  
C Representative H&E staining of liver sections after three weeks of treatment.  
 
 
Figure 6. Reversion of pre-existing metastases by the CD44v6 peptide.  
A Schematic representation of the experimental procedure. ASv6 cells were injected 
in rats. Treatment with rv6pep or control peptide (mouse) started after three weeks. 
After 21 additional days the animals were sacrificed and analyzed for lung 
metastases. The quantification represents the average number of metastases. The 
group size is given in Table S6.  
B Schematic representation of the experimental procedure. L3.6pl were injected in 
mice. Representative pictures of livers from tumor-bearing mice treated with hv6pep 
or control peptide (rat). Arrows indicate metastases. The quantification shows the 
average number of metastases.  The group size is given in Table S3.  
C Schematic representation of prolonged survival of animals receiving hv6pep. Bar 
chart representing the average tumor size before treatment start, after end of 
treatment with hv6pep for 35 days (hv6pep group1) and after 49 days without 
treatment (hv6pep group 2). 
 
Figure 7. The CD44v6 peptide induces apoptosis in already established 
metastases.  
Three weeks after injection of ASv6 tumor cells, animals received an injection of 
rv6pep or control peptide every second day. At the indicated days, one animal of 
each group was sacrificed. Apoptosis in lung was monitored using an antibody 
against cleaved Caspase-3 and cleaved Caspase-8. The area of the metastase is 
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marked (M). The magnification is 4,5x. The experiment was performed two times with 
similar outcome. 
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Supplementary Materials and Methods 
Lentiviral transfection of shRNA 
The lentivirus system used for silencing Met has already been described12.  
 
Western Blot (WB) analysis 
Serum-starved cells (24 hours) were induced with HGF (10 ng/ml) at 37°C for 5 
minutes. Where indicated, cells were treated with peptides (100 ng/ml) prior to 
induction at 37°C, 10 minutes. Cells were then lysed in SDS-sample buffer containing 
100 mM DTT, boiled and subjected to WB analysis. The intensity of the WB bands 
was quantified with the program Image J (National Institutes of Health).  
 
CellPlayerTM 96-well kinetic cell migration assay 
The effect of mv6pep and Crizotinib on cell migration was assessed using FC1245 
cells. Cells were grown to confluency in 96 well Essen ImageLock plates (Essen 
Bioscience, Ann Arbor, USA). Precise wounds were created in all wells of the 96 well 
plate using a 96-pin Wound Maker. Cells were gently washed and treated for 2 hours 
with PBS (vehicle), increasing concentrations of v6pep (0.025µM-0.5µM), and 
Crizotinib (0.5µM). Plates were placed inside the IncuCyte ZOOM imaging system 
(Essen Bioscience) and scans were made every 2 hours. Wound confluence metrics 
were quantified and analyzed with IncuCyte software. 
 
Quantitative determination of human HGF and VEGF in cell culture supernatant 
Human HGF and VEGF levels in cell culture medium of L3.6pl cells were detected 
using the Quantikine Human HGF Immunoassay and Quantikine Human VEGF 
Immunoassay from R&D Systems (Wiesbaden, Germany). 3x106 cells were cultured 
for 5 days in a 15 cm plate with hv6pep. Assays were performed according to 
manufacturer’s instructions. 
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Serum stability of peptide 
Stability of a of EQWFGNRWHEGY in human serum (Sigma-Aldrich, Taufkirchen, 
Germany) at 37 °C. Samples were taken after the individual incubation times, 
precipitated with the twofold volume of acetonitrile; the supernatant (7µL) was 
analyzed by HPLC (5 min 0-50% acetonitrile/water, 0.1% TFA, 2mL/min, Merck 
Millipore Chromolith Performance RP-18e 100-3 mm, ambient temperature). The 
degradation proceeds via multiple intermediates, for example EQWFGNRWHE, 
EQWFGNRW or FGNRWHE was detected by LCMS. 
 
Animal experiments 
For the rat syngeneic model, 1x106 cells were subcutaneously injected into the right 
posterior flank of the animals. Tumors developed for four weeks. During this time 
period animals injected with ASv6 cells expressing Met shRNA or control shRNA 
received doxycycline in drinking water. At the end of the experiment, primary tumors 
were isolated. Lungs and axillary lymph nodes were analyzed. The tissues were fixed 
in 4% Formalin and embedded in paraffin for analysis. Where indicated animals 
received 200 µg of peptide or antibody per i.v. or i.t. injection three times per week for 
four weeks. Treatment of rats with a hundred fold higher single dose of peptide 
showed no acute toxicity (study performed at LPT Hamburg, Germany, study 
protocol available upon request). Tumor growth was monitored weekly using a 
caliper. Animals were killed at day 30 after start of the treatment. 
For the human orthotopic model, L3.6pl cells (passage 24-26) were suspended in 
Hank’s balanced salt solution (Invitrogen) after trypsinization. The cells were injected 
into the pancreas of male nude mice as described15. Mice were injected i.p. 7 days 
later with hv6pep respectively control peptide (20 µg). The injection was repeated 
three times per week for 21 days. i.p. injection was used instead of i.v. or i.t. as in 
rats since thrice weekly i.v. injection in mice is technically problematic. Two days 
after the last treatment animals were killed. The orthotopic implantation of Panc1 
cells was performed accordingly.  For the syngeneic FC1245 model, B6 mice were 
shaved prior to implantation of 5x105 cells. Treatment was performed with 20µg of 
mv6pep respectively control peptide (rat) thrice weekly.  
JoPaca-1 cells (low passage) were injected orthotopically in the pancreas as 
described (Fredebohm et al., PloS one, 2012). Animals were treated for 80 days with 
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20µg of hv6pep  respectively control peptide (rat) thrice weekly. Of note, even the 
extended treatment of the animals for 10 weeks with the peptide in the JoPaca model 
had no impact on the body weight (Fig. 4B) demonstrating the negligible toxicity of 
the peptide.  
 
Genetically engineered mice 
LSL-KrasG12D, LSL-Trp53R172H, Pdx1-Cre (KPC) mice have been described 
previously (Hingorani et al., 2005).  KPC mice on a mixed strain background were 
kept in conventional animal facilities and given access to standard diet and water ad 
libitum. All experiments were performed in compliance with UK Home Office 
guidelines under licence approved by the local ethics committee. Mice were 
genotyped by Transnetyx (Cordova, Tennessee, USA) and monitored at least 3 times 
per week.  Mice were treated with 20µg mv6pep or control peptide 3 times per week 
by intraperitoneal injection. Mice at end-point were sacrificed as per institutional 
guidelines, and tissues harvested and fixed in 10% neutral buffered formalin.  
 
To examine the regression of metastases, either ASv6 or L3.6pl, were implanted as 
described above. Tumor growth was allowed for three weeks. At that time all animals 
had developed metastases in the control group. Animals were then injected i.p. with 
20 µg (L3.6pl model: hv6pep or control peptide) or i.v. with 200 µg (rat model: rv6pep 
or control peptide) of peptides three times per week. Animals were killed 23 days 
after the start of the treatment. 
To investigate a prolonged survival with hv6pep in the L3.6pl model animals were 
orthotopically injected with tumor cells as described above. Average tumor volume 
was determined for control animals after one week. Then animals were treated with 
hv6pep as described for 35 days. Animals of hv6pep group 1 were sacrificed to 
determine the tumor size. The tumor size of animals of the hv6pep group 2 was 
determined after additional 45 days without treatment. 
Tumors were measured using an electronic caliper. The volume was determined 
using the formula: volume = length x width x length x 0,5. Standard deviations (SD) 
were calculated using Student’s T-Test (*p<0,05, **p<0,01, ***p<0,001). 
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In vivo imaging using Optix MX2 
In vivo imaging of the subcutaneously grown ASv6 tumors in BDX rats was 
performed using the near infrared fluorescence (NIRF)-imaging system Optix MX2 
(ART, Montreal, Canada). To avoid autofluorescence of fur, rats were shaved around 
the tumor. Subsequently, animals were anesthetized using 2% isoflurane and gently 
fixed on the devices´ warm plate for the entire time of data acquisition. To reduce 
fluorescence background, rats were fed with chlorophyll-reduced food (Provimi Kliba 
AG, Kaiseraugst, Switzerland) for one week prior NIRF imaging. All in vivo analyses 
were preceded by native scans of animals without any injection of the fluorescent 
probe. Rats were injected with 200 µg rv6pep DY681 or mv6pep DY681 (control) via 
the tail vein. Data were acquired at the indicated time after injection of the peptides. 
For ex vivo monitoring animals were sacrificed after 24 hours after peptide injection 
and tumor and organs of interest were scanned ex vivo using Optix MX2.   
DY681 fluorescence was measured using excitation at 670 nm in combination with a 
700 nm long-pass emission filter. Scans were performed with 1.5 mm raster, photon 
collection time of 0.5-1 s per scan point and varying laser power. Data sets were 
analyzed with OptiView (ART). Fluorescence intensity data are displayed in 
normalized counts (NC) where the measured fluorescence intensity (counts) was 
normalized for varying laser power and integration times, allowing comparison of 
measurements with different settings. 
 
In vivo imaging using Pearl imager 
In vivo imaging of the mice with the L3.6pl tumors was performed using the Pearl™ 
Imager (LI-COR Biosciences, Bad Homburg, Germany). The system uses two lasers 
(685 and 785 nm) for excitation and a charge-coupled device detector for signal 
detection. In order to standardize the images we made use of the Pearl Cam 
Software. Prior to imaging the mice were anesthetized with 2.0% isoflurane. Animals 
were placed on the warm plate of the imager and continuous delivery of isofluorane 
was achieved through a nose cone in the imaging drawer. Images were captured at 
white light, 700 and 800 nm. Animals were imaged prior to peptide injection and 24 
hours after injection with either hv6pep DY681 or rv6pep DY681 as control. 
Immediately after each imaging session animals were killed, tumor, liver and spleen 
isolated and scanned ex vivo.  
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Immunofluorescence  
ASv6 or L3.6pl cells were seeded at 5,000 cells/well of a Lab-TekR Chamber SlideTM 
(Nunc, Napierville, IL, USA). On the following day the cells were washed with cold 
PBS and fixed with 4% Formalin for 30 min at RT. Unspecific binding was blocked 
with 1% BSA in PBS for 1 hour at RT. The cells were incubated for 1 hour with the 
DY681-labeled peptides. After washing steps with PBS the cover slips were mounted 
with Fluorescence Mounting Medium (Dako, Glostrup, Denmark) and the 
immunofluorescence was measured by a laser scanning confocal microscope Leica 
TCS2 SP2 (Exton, PA, USA) and processed using Leica confocal software. A 20x 
objective was used for imaging. 
 
Histology 
For histo-morphological analysis paraffin-embedded sections of lungs were stained 
with H&E or PAS. Serial sections of whole tissue blocks were examined by analyzing 
sections every 20 µm; in each slice, presence and extension of metastatic deposit 
was assessed.  
 
Immunohistological and immunofluorescence analysis  
Paraffin sections were deparaffinized and rehydrated. For P-Met staining antigen 
unmasking was achieved by boiling the slides in 1 mM EDTA pH 8,0 followed by 
incubation for 15 min at a sub-boiling temperature, for CD31 staining the sections 
were treated with Proteinase K (8µg/ml) for 10 min at 37°C. For immunofluorescence 
staining of P-Met and P-VEGFR-2, blocking was performed with 5% goat serum 
(Dako) for 60 minutes. For immunohistochemistry endogenous peroxidases were at 
first blocked with 3% H2O2 in PBS followed by incubation with biotin blocking system 
(Dako) and then unspecific binding was inhibited by incubation with 5% FCS in PBS. 
The sections were incubated with the P-Met antibody, P-VEGFR-2 antibody, Met 
antibody, GFP antibody, CD31 antibody or VFF18 o/n at 4°C. PBS-washed sections 
were incubated with Alexa Fluor R 546 goat anti-rabbit or a biotinylated secondary 
antibody (for IHC-stainings rabbit anti–rat antibody for VFF18 and CD31, goat anti-
rabbit for P-Met, cleaved Caspase-3 and cleaved Caspase-8 and rabbit anti-mouse 
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for GFP) for 45 minutes. For DAB staining the sections were treated with a 
streptavidin-peroxidase conjugate (Dako) and developed with DAB substrate system 
(Biozol, Eching, Germany). For immunofluorescence DAPI was used for nuclear 
staining. 
 
 
RNA-seq in PDAC-Patients:  
Genome-wide RNA-sequencing (RNAseq) based gene expression data were 
generated by TCGA consortium using Illumina HiSeq 2000 RNA Sequencing 
platform as previously documented [5] [1]. RNAseq data for 136 pancreatic ductal 
adenocarcinoma (PDAC) patients were obtained from the portal [https://tcga-
data.nci.nih.gov/tcga] and the clinical characteristics is provided in the supplemental 
Table.. (xls). Level 3 RNASeq data contain expression quantification for genes, 
isoforms, exons and junctions. Isoform transcript quantification was analyzed 
separately in this study. The original method of quantification followed was the Reads 
Per Kilobase of exon model per Million mapped reads [8] The calculation of gene 
expression levels relied on the version 2 algorithm (RNASeqV2), i.e., for generation 
of level three data a combination of MapSlice and RSEM software packages for 
sequence assignment and estimation of sequence abundance was utilized [3,6,10] 
Transcript-based analysis: 
Annotation of transcripts: 
Transcript IDs in the TCGA RNAseq data are annotated according to UCSC build 
2009. The University of North Carolina – Chapel Hill online directory provides TCGA 
related files that are necessary for our analysis: 
-­‐ First, to identify which transcripts IDs detect CD44 expression, the file `` 
https://webshare.bioinf.unc.edu/public/mRNAseq_TCGA/rsem_ref/unc_known
ToLocus.txt´´ was retrieved. In brief, it links every UCSC transcript ID to the 
corresponding gene of interest. 11 transcripts in total were assigned to CD44. 
-­‐  The sequences for each of these transcripts were retrieved from `` 
https://webshare.bioinf.unc.edu/public/mRNAseq_TCGA/rsem_ref/hg19_M_rC
RS_ref.transcripts.fa`` 
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Identification of transcripts of interest: 
In our previous paper[7], a three amino acid sequence within the v6 sequence which 
was identified by mutational analysis to be essential for the co-receptor function of c-
met and HGF. The sequence was RWH in humans. To identify which transcripts in 
the TCGA contain the v6 sequence, we used ExPASY [2] to translate the mRNA 
sequence of each transcript (11 in total) into amino acids. Only two transcripts, 
uc001mvv.2 and uc001mvu.2 were found to encode for the RWH amino acid 
sequence and therefore, were considered to be v6 containing/surrogates for v6 
expression. Other transcripts lacking the critical v6 region were considered CD44 
delta v6.   
Data pre-processing: 
The SUMO software package, developed in house, was used for data pre-processing 
``http://angiogenesis.dkfz.de/oncoexpress/software/sumo/``. In brief, three steps of 
further processing were performed to RNAseqV2 data before analysis. Four 
transcripts with more than 20% zero values were filtered from our analysis 
(uc001mvy.2, uc009ykh.2, uc010rer.1, uc010ret.1). Pre-processing included virtual 
pool normalization of expression data for each individual transcript. Hierarchical 
clustering was performed using Chebyshev distance and complete linkage. Kaplan-
Meier survival estimates were employed to examine potential differences in survival 
between patients who clustered to have a higher tumor expression of v6-containing 
transcripts (v6 Up) versus patients with a lower tumor expression of v6-containing 
transcripts (v6 Down). A p-value <0.05 by Log rank-test was considered statistically 
significant  
Clinical characteristics: 
The patient characteristics of the TCGA cohort are found in supplementary xls.file 
(X). Clinical data from the TCGA portal was downloaded and compiled into a matrix 
by an in-house software Table-Butler. The v6 Up and v6 Down patient groups were 
compared for differential enrichment in patient annotations by classical student`s t-
test, chi-square or Fisher`s exact test where applicable.  Patients in both groups were 
balanced for all demographic characteristics and treatment characteristics. In the v6 
Up group, patients had significantly increased odds ratio of metastasis (44%) versus 
23% of patients in the v6 down group (p=0.01). 
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Figure legends supplement 
 
Figure S1.  A CD44v6 specific peptide blocks tumor metastasis 
Left: Top: Treatment scheme. Bottom: ASv6 cells were injected as described. After 
one week the animals were treated with rv6pep (i.t.) or PBS. Axillary lymph nodes 
(left) and lungs (right) were analyzed for metastases. The arrows indicate 
metastases. The animal number is given in Table 2. 
Right: Bar chart representing the average number of metastases.  
 
Figure S2.  Binding of the CD44v6 peptide to primary tumors and metastases in 
vivo.  
A Left side: ASv6 cells were induced with HGF in the presence of rv6pep DY681 
respectively control peptide (mv6pep DY681) and ERK activation was measured. 
Right side: ASv6 cells were fixed and stained with the indicated peptides for one 
hour. Fluorescence and bright field images were taken using a laser scanning 
confocal microscope (Leica TCS2 SP2) with a 20x objective. The experiment was 
performed 2 times.  
B Rats bearing a subcutaneous tumor of ASv6 cells were injected i.v. with 200 µg of 
indicated peptides and analyzed by NIRF imaging using Optix MX2 (ART, Montreal, 
Canada). Fluorescence intensities are displayed in normalized counts (NC). Series of 
fluorescent data sets obtained at the indicated time points after injection are shown. 
Red circle: Position of the tumor. The experiment was performed two times.  
C Top: Rats bearing a subcutaneous tumor of ASv6 cells injected i.v. with 200 µg of 
indicated peptides. Bottom: Tumors and lungs were excised and fluorescence of the 
labeled peptides was monitored. 
 
Figure S3: The CD44v6 peptide inhibits cell migration 
A Phase-contrast images with the IncuCyte ZOOM imaging system of FC1245 cells 
from wells taken at different time points.  
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B Top: The wound closure was analyzed with IncuCyte software. Time-course of 
migration following treatment with PBS, different concentrations of mv6pep or 
Crizotinib. Bottom: Statistical analysis of the wound closure after twelve hours. 
 
Figure S4. Specific accumulation of hv6pep in primary tumors and metastases 
of the L3.6pl human pancreatic cancer model.  
A Left side: L3.6pl cells were induced with HGF in the presence of the indicated 
peptides and ERK activation was determined. Right side: L3.6pl cells were stained 
either with the hv6pep DY681 or rv6pep DY681. Images were taken with the laser 
scanning confocal microscope (Leica TCS2 SP2). This experiment was repeated two 
times. Magnification: 20x.  
B L3.6pl tumors were orthotopically implanted for three weeks as has been 
described15 followed by one i.v. injection of the indicated peptides (20 µg). Binding of 
peptides was analyzed 24 hours after injection in anesthetized mice using the Pearl® 
Impulse Small Animal Imaging System (Li-Cor Biosciences). Each group consisted of 
three animals.  
C Tumors, livers and spleens of all animals used in B were excised and fluorescence 
of the labeled peptides was monitored. Results for all animals were similar. The 
scales at the side indicate the synchronized signal intensity. 
 
Figure S5. A Representative immunofluorescence staining of L3.6pl tumors from the 
hv6pep or control peptide treated animals for phospho-Met, Met and phospho-
VEGFR-2. Analysis of five animals per group gave similar results. 
B Human HGF and VEGF levels produced by L3.6pl cells in presence and absence 
of the hv6pep (200 ng/ml in the culture medium). Bars reflect average levels from 
triplicates obtained in three independent experiments. 
C Staining of L3.6pl tumors for CD31. Magnification 50x. Graphs show the average 
vessel numbers respectively vessel size calculated from five tumors.  
 
 
Figure S6.  The v6 peptide reduces growth of Panc1 tumors 
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A Panc1 cells were treated with hv6pep or control pep (rat) prior to induction with 10 
ng/ml HGF. Met and ERK activation were determined in western blot.  
B Proliferation assay of Panc1 cells in absence and presence of HGF (20 ng/ml) and 
after preincubation with hv6pep (500 ng/ml). After 72 hours cells were counted using 
a brightfield microscope. The cell numbers were compared to the seeded cell 
number. Samples were measured in triplicates.  
C HGF-induced migration and invasion of Panc1 cells using a transwell assay. Cells 
were treated with hv6pep or control peptide prior to induction with HGF 50 ng/ml in a 
Boyden chamber assay. After 24 hours cells were harvested from the bottom side of 
the filter and stained with crystal violet. 
D Pictures of the tumor and pancreas after treatment with hv6pep respectively 
control peptide (top). Average tumor volume after three weeks of treatment (bottom).  
 
Fig. S7 Serum stability of hv6pep (KEQWFGNRWHEGYR, A) and 
EQWFGNRWHEGY (B). Samples from a 500 µM solution of either one of the 
peptides in human serum at 37 °C were taken at the indicated times, precipitated 
with the twofold volume of acetonitrile and 7 µL of the supernatant analyzed by 
HPLC.  The major metabolites in A were identified by LCMS as 
KEQWFGNRWHEGY (#) and EQWFGNRWHE (*). 
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